<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35552484</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>17</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>18</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2045-2322</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>12</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
              <Day>12</Day>
            </PubDate>
          </JournalIssue>
          <Title>Scientific reports</Title>
          <ISOAbbreviation>Sci Rep</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Arginase 1 is a marker of protection against illness in contacts of leprosy patients.</ArticleTitle>
        <Pagination>
          <StartPage>7850</StartPage>
          <MedlinePgn>7850</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">7850</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-022-11944-9</ELocationID>
        <Abstract>
          <AbstractText>Leprosy household contacts are generally more prone to develop the disease compared to the general population. Previous studies have demonstrated that genes related to the alternative activation (M2) profile in macrophages are associated with the increased bacillary load in multibacillary leprosy patients (MB), and that contacts of MB patients have a higher risk of contracting the disease. In addition, positive serological responses to PGL-1 or LID-1 are associated with a higher risk of disease. We performed a 5-year follow-up of contacts of leprosy patients and evaluated the pattern of gene and protein expression in cells from contacts that developed leprosy during this period. Leprosy household contacts had decreased soluble CD163 and heme oxygenase 1 (HO-1) serum levels when compared with healthy donors and leprosy patients. In contrast, arginase 1 activities were higher in contacts when compared with both healthy donors and leprosy patients. Of the contacts, 33 developed leprosy during the follow-up. Gene expression analysis revealed reduced ARG1 expression in these contacts when compared with contacts that did not develop disease. Arginase activity was a good predictive marker of protection in contacts (sensitivity: 90.0%, specificity: 96.77%) and the association with serology for anti-PGL-1 and anti-LID-1 increased the sensitivity to 100%. Altogether, the data presented here demonstrate a positive role of arginase against leprosy and suggest that the evaluation of arginase activity should be incorporated into leprosy control programs in order to aid in the decision of which contacts should receive chemoprophylaxis.</AbstractText>
          <CopyrightInformation>© 2022. The Author(s).</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>da Silva Prata</LastName>
            <ForeName>Rhana Berto</ForeName>
            <Initials>RB</Initials>
            <AffiliationInfo>
              <Affiliation>Leprosy Laboratory, Oswaldo Cruz Institute, Oswaldo Cruz Foundation, Avenida Brasil, 4365, Manguinhos, Rio de Janeiro, RJ, 21040-360, Brazil.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Inflammation and Immunity Laboratory, Federal University of Rio de Janeiro, Rio de Janeiro, RJ, Brazil.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mendes</LastName>
            <ForeName>Mayara Abud</ForeName>
            <Initials>MA</Initials>
            <AffiliationInfo>
              <Affiliation>Leprosy Laboratory, Oswaldo Cruz Institute, Oswaldo Cruz Foundation, Avenida Brasil, 4365, Manguinhos, Rio de Janeiro, RJ, 21040-360, Brazil.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Soares</LastName>
            <ForeName>Vinicius Cardoso</ForeName>
            <Initials>VC</Initials>
            <AffiliationInfo>
              <Affiliation>Immunopharmacology Laboratory, Oswaldo Cruz Institute, Oswaldo Cruz Foundation, Rio de Janeiro, RJ, Brazil.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>França-Costa</LastName>
            <ForeName>Jaqueline</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Immunology Service, Professor Edgar Santos University Hospital, Federal University of Bahia, Salvador, Brazil.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Inflammation and Biomarkers Laboratory, Gonçalo Moniz Institute, Oswaldo Cruz Foundation, Salvador, BA, Brazil.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sales</LastName>
            <ForeName>Anna Maria</ForeName>
            <Initials>AM</Initials>
            <AffiliationInfo>
              <Affiliation>Leprosy Laboratory, Oswaldo Cruz Institute, Oswaldo Cruz Foundation, Avenida Brasil, 4365, Manguinhos, Rio de Janeiro, RJ, 21040-360, Brazil.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Duppré</LastName>
            <ForeName>Nádia Cristina</ForeName>
            <Initials>NC</Initials>
            <AffiliationInfo>
              <Affiliation>Leprosy Laboratory, Oswaldo Cruz Institute, Oswaldo Cruz Foundation, Avenida Brasil, 4365, Manguinhos, Rio de Janeiro, RJ, 21040-360, Brazil.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>de Matos Borges</LastName>
            <ForeName>Valéria</ForeName>
            <Initials>V</Initials>
            <AffiliationInfo>
              <Affiliation>Inflammation and Biomarkers Laboratory, Gonçalo Moniz Institute, Oswaldo Cruz Foundation, Salvador, BA, Brazil.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>da Silva</LastName>
            <ForeName>Tatiana Pereira</ForeName>
            <Initials>TP</Initials>
            <AffiliationInfo>
              <Affiliation>Leprosy Laboratory, Oswaldo Cruz Institute, Oswaldo Cruz Foundation, Avenida Brasil, 4365, Manguinhos, Rio de Janeiro, RJ, 21040-360, Brazil.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bozza</LastName>
            <ForeName>Patricia Torres</ForeName>
            <Initials>PT</Initials>
            <AffiliationInfo>
              <Affiliation>Immunopharmacology Laboratory, Oswaldo Cruz Institute, Oswaldo Cruz Foundation, Rio de Janeiro, RJ, Brazil.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bozza</LastName>
            <ForeName>Marcelo Torres</ForeName>
            <Initials>MT</Initials>
            <AffiliationInfo>
              <Affiliation>Inflammation and Immunity Laboratory, Federal University of Rio de Janeiro, Rio de Janeiro, RJ, Brazil.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sarno</LastName>
            <ForeName>Euzenir Nunes</ForeName>
            <Initials>EN</Initials>
            <AffiliationInfo>
              <Affiliation>Leprosy Laboratory, Oswaldo Cruz Institute, Oswaldo Cruz Foundation, Avenida Brasil, 4365, Manguinhos, Rio de Janeiro, RJ, 21040-360, Brazil.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Moraes</LastName>
            <ForeName>Milton Ozório</ForeName>
            <Initials>MO</Initials>
            <AffiliationInfo>
              <Affiliation>Leprosy Laboratory, Oswaldo Cruz Institute, Oswaldo Cruz Foundation, Avenida Brasil, 4365, Manguinhos, Rio de Janeiro, RJ, 21040-360, Brazil.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sperandio da Silva</LastName>
            <ForeName>Gilberto Marcelo</ForeName>
            <Initials>GM</Initials>
            <AffiliationInfo>
              <Affiliation>Clinical Research Laboratory in Chagas Disease, National Institute of Infectology Evandro Chagas, Oswaldo Cruz Foundation, Rio de Janeiro, RJ, Brazil.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pinheiro</LastName>
            <ForeName>Roberta Olmo</ForeName>
            <Initials>RO</Initials>
            <AffiliationInfo>
              <Affiliation>Leprosy Laboratory, Oswaldo Cruz Institute, Oswaldo Cruz Foundation, Avenida Brasil, 4365, Manguinhos, Rio de Janeiro, RJ, 21040-360, Brazil. robertaolmo@gmail.com.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>05</Month>
          <Day>12</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Sci Rep</MedlineTA>
        <NlmUniqueID>101563288</NlmUniqueID>
        <ISSNLinking>2045-2322</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000907">Antibodies, Bacterial</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000942">Antigens, Bacterial</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D006017">Glycolipids</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.5.3.1</RegistryNumber>
          <NameOfSubstance UI="D001119">Arginase</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000907" MajorTopicYN="N">Antibodies, Bacterial</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000942" MajorTopicYN="N">Antigens, Bacterial</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001119" MajorTopicYN="N">Arginase</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006017" MajorTopicYN="N">Glycolipids</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007918" MajorTopicYN="Y">Leprosy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009166" MajorTopicYN="Y">Mycobacterium leprae</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>The authors declare no competing interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>2</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>28</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>13</Day>
          <Hour>14</Hour>
          <Minute>19</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35552484</ArticleId>
        <ArticleId IdType="pmc">PMC9098644</ArticleId>
        <ArticleId IdType="doi">10.1038/s41598-022-11944-9</ArticleId>
        <ArticleId IdType="pii">10.1038/s41598-022-11944-9</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Palit A, Kar HK. Prevention of transmission of leprosy: the current scenario. Indian J. Dermatol. Venereol. Leprol. 2020;86:115–123. doi: 10.4103/ijdvl.IJDVL_326_19.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4103/ijdvl.IJDVL_326_19</ArticleId>
            <ArticleId IdType="pubmed">31975697</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fischer E, Vlas DS, Meima A, Habbema D, Richardus J. Different mechanisms for heterogeneity in leprosy susceptibility can explain disease clustering within households. PLoS ONE. 2010;5(11):e14061. doi: 10.1371/journal.pone.0014061.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0014061</ArticleId>
            <ArticleId IdType="pmc">PMC2988824</ArticleId>
            <ArticleId IdType="pubmed">21124916</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>World Health Organization  Global leprosy (hansen disease) update, 2019: time to step-up prevention initiative. Wkly Epidemiol Rep. 2020;95:417–440.</Citation>
        </Reference>
        <Reference>
          <Citation>Schoenmakers A, Hambridge T, Van Wijk R, Kasang C, Richardus JH, Bobosha K, et al.  PEP4LEP study protocol: Integrated skin screening and SDR-PEP administration for leprosy prevention: Comparing the effectiveness and feasibility of a community-based intervention to a health centre-based intervention in Ethiopia, Mozambique and Tanzania. BMJ Open. 2021;11(8):e046125. doi: 10.1136/bmjopen-2020-046125.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/bmjopen-2020-046125</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sarno EN, Duppre NC, Sales AM, Hacker MA, Nery JA, de Matos HJ. Leprosy exposure, infection and disease: a 25-year surveillance study of leprosy patient contacts. Mem Inst Oswaldo Cruz. 2012;107(8):1054–1059. doi: 10.1590/S0074-02762012000800015.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1590/S0074-02762012000800015</ArticleId>
            <ArticleId IdType="pubmed">23295758</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Penna MLF, Penna GO, Iglesias PC, Natal S, Rodrigues LC. Anti-PGL-1 positivity as a risk marker for the development of leprosy among contacts of leprosy cases: systematic review and meta-analysis. PLoS Negl Trop Dis. 2016;10(5):e0004703. doi: 10.1371/journal.pntd.0004703.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pntd.0004703</ArticleId>
            <ArticleId IdType="pmc">PMC4871561</ArticleId>
            <ArticleId IdType="pubmed">27192199</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>de Almeida EC, Martinez AN, Maniero VC, Sales AM, Duppre NC, Sarno EN, et al.  Detection of Mycobacterium leprae DNA by polymerase chain reaction in the blood and nasal secretion of Brazilian household contacts. Mem Inst Oswaldo Cruz. 2004;99(5):509–511. doi: 10.1590/S0074-02762004000500009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1590/S0074-02762004000500009</ArticleId>
            <ArticleId IdType="pubmed">15543415</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Job CK, Jayakumar J, Kearney M, Gillis TP. Transmission of leprosy: a study of skin and nasal secretions of household contacts of leprosy patients using PCR. Am J Trop Med Hyg. 2008;78(3):518–521. doi: 10.4269/ajtmh.2008.78.518.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4269/ajtmh.2008.78.518</ArticleId>
            <ArticleId IdType="pubmed">18337353</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Düppre NC, Camacho LAB, Sales AM, Illarramendi X, Nery JAC, Sampaio EP, et al.  Impact of PGL-1 seropositivity on the protective effect of BCG vaccination among leprosy contacts: a cohort study. PLoS Negl Trop Dis. 2012;6(6):e1711. doi: 10.1371/journal.pntd.0001711.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pntd.0001711</ArticleId>
            <ArticleId IdType="pmc">PMC3378622</ArticleId>
            <ArticleId IdType="pubmed">22724040</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Düppre NC, Camacho LAB, da Cunha SS, Struchiner CJ, Sales AM, Nery JAC, Sarno EN. Effectiveness of BCG vaccination among leprosy contacts: a cohort study. Trans. R. Soc. Trop. Med. Hyg. 2008;102:631–638. doi: 10.1016/j.trstmh.2008.04.015.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.trstmh.2008.04.015</ArticleId>
            <ArticleId IdType="pubmed">18514242</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Niitsuma ENA, Bueno I de C, Arantes EO, Carvalho APM, Junior GFX, Fernandes G da R, Lana FCF. Factors associated with the development of leprosy in contacts: a systematic review and meta-analysis. Rev Bras Epidemiol. 24, e210039 (2021).</Citation>
        </Reference>
        <Reference>
          <Citation>van Hooij A, Geluk A. In search of biomarkers for leprosy by unraveling the host immune response to Mycobacterium leprae. Immunol. Rev. 2021;301(1):175–192. doi: 10.1111/imr.12966.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/imr.12966</ArticleId>
            <ArticleId IdType="pmc">PMC8251784</ArticleId>
            <ArticleId IdType="pubmed">33709405</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fulco T de O, Andrade PR, Barbosa MG de M, Pinto TGT, Ferreira PF, Ferreira H, Nery JAC, Corte-Real S, Borges VM, Moraes MO, Sarno EN, Sampaio EP, Pinheiro RO. Effect of apoptotic cell recognition on macrophage polarization and mycobacterial persistence. Infect Immun. 82 (9), 3968–3978 (2014).</Citation>
        </Reference>
        <Reference>
          <Citation>Moura DF, de Mattos KA, Amadeu TP, Andrade PR, Sales JS, Schmitz V, et al.  CD163 favors Mycobacterium leprae survival and persistence by promoting anti-inflammatory pathways in lepromatous macrophages. Eur J Immunol. 2012;42(11):2925–2936. doi: 10.1002/eji.201142198.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/eji.201142198</ArticleId>
            <ArticleId IdType="pubmed">22851198</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>de Mattos Barbosa MG, da Silva Prata RB, Andrade PR, Ferreira H, de Andrade Silva BJ, da Paixão de Oliveira JA, et al. Indoleamine 2,3-dioxygenase and iron are required for Mycobacterium leprae survival. Microbes Infect. 19 (11), 505–514 (2017).</Citation>
        </Reference>
        <Reference>
          <Citation>Tió-Coma M, Kiełbasa SM, van den Eeden SJF, Mei H, Roy JC, Wallinga J, et al.  Blood RNA signature RISK4LEP predicts leprosy years before clinical onset. EBioMedicine. 2021;68:103379. doi: 10.1016/j.ebiom.2021.103379.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ebiom.2021.103379</ArticleId>
            <ArticleId IdType="pmc">PMC8182229</ArticleId>
            <ArticleId IdType="pubmed">34090257</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>van Hooij A, Tió-Coma M, Verhard EM, Khatun M, Alam K, Tjon Kon Fat E, et al. Household contacts of leprosy patients in endemic areas display a specific innate immunity profile. Front Immunol. 11, 1811 (2020).</Citation>
        </Reference>
        <Reference>
          <Citation>Carvalho APM, da Conceição Oliveira Coelho Fabri A, Corrêa Oliveira R, Lana CF. Factors associated with anti-phenolic glycolipid-I seropositivity among the household contacts of leprosy cases. BMC Infect Dis. 15 (1), 219 (2015)</Citation>
        </Reference>
        <Reference>
          <Citation>Amorim FM, Nobre ML, Ferreira LC, Nascimento LS, Miranda AM, Monteiro GRG, et al.  Identifying leprosy and those at risk of developing leprosy by detection of antibodies against LID-1 and LID-NDO. PLoS Negl Trop Dis. 2016;10(9):e0004934. doi: 10.1371/journal.pntd.0004934.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pntd.0004934</ArticleId>
            <ArticleId IdType="pmc">PMC5033353</ArticleId>
            <ArticleId IdType="pubmed">27658042</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>de Carvalho FM, Rodrigues LS, Duppre NC, Alvim IMP, Ribeiro-Alves M, Pinheiro RO, et al.  Interruption of persistent exposure to leprosy combined or not with recent BCG vaccination enhances the response to Mycobacterium leprae specific antigens. PLoS Negl Trop Dis. 2017;11(5):e0005560. doi: 10.1371/journal.pntd.0005560.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pntd.0005560</ArticleId>
            <ArticleId IdType="pmc">PMC5432189</ArticleId>
            <ArticleId IdType="pubmed">28467415</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Adams, L. B., S. G. Franzblau, Z. Vavrin, J. B. Hibbs, e J. L. Krahenbuhl. L-Arginine-Dependent Macrophage Effector Functions Inhibit Metabolic Activity of Mycobacterium leprae. J Immunol. 147 (5), 1642–1646 (1991).</Citation>
        </Reference>
        <Reference>
          <Citation>Souza-Moreira L, Soares VC, Dias S da SG, Bozza PT. Adipose-derived mesenchymal stromal cells modulate lipid metabolism and lipid droplet biogenesis via AKT/mTOR –PPARγ signalling in macrophages. Sci Rep. 9 (1), 20304 (2019).</Citation>
        </Reference>
        <Reference>
          <Citation>Duthie MS, Goto W, Ireton GC, Reece ST, Cardoso LPV, Martelli CMT, et al.  Use of protein antigens for early serological diagnosis of leprosy. Clin Vaccine Immunol. 2007;14(11):1400–1408. doi: 10.1128/CVI.00299-07.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/CVI.00299-07</ArticleId>
            <ArticleId IdType="pmc">PMC2168166</ArticleId>
            <ArticleId IdType="pubmed">17898185</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
